This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): NovoMix, NovoRapid Mix, insulin aspart [rDNA origin] protamine suspension & insulin aspart [rDNA origin] injection, biphasic insulin aspart (BIAsp)
Description: NovoLog Mix contains protaminated insulin aspart (intermediate acting insulin) and insulin aspart (rapid acting insulin). The NovoLog Mix 70/30 formulation in the US is similar to the NovoMix 30 formulation in Europe, and has a rapid onset and intermediate duration of action, so insulin needs immediately after a meal and between meals can be met through a single injection rather than separate injections of these types of insulins. Additionally, there is a 50/50 mix and a 30/70 mix; the latter is only available in Europe.
NovoLog Mix News
Additional information available to subscribers only: